Quantitative targeted proteomics for membrane transporter proteins: Method and application

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 714-726

  Qiu, Xi ^a   Zhang, Hui ^b   Lai, Yurong ^a,c  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

^c NONE   (United States)

Author keywords

drug absorption, distribution, metabolism, and excretion (ADME); drug transporters; in vitro in vivo and in vivo in vivo extrapolations (IVIVE); LC MS MS; quantitative targeted proteomics

Indexed keywords

BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; MEMBRANE PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER B; ORGANIC CATION TRANSPORTER 1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; CARRIER PROTEIN; DRUG;

DATA BASE; HUMAN; ION TRAP MASS SPECTROMETRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR PROBE; MULTIPLE REACTION MONITORING TRANSITION; NONHUMAN; PEPTIDE ANALYSIS; PHASE TRANSITION; PROCESS OPTIMIZATION; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SELECTED REACTION MONITORING TRANSITION; SENSITIVITY ANALYSIS; STANDARD; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM;

ANIMALS; DRUG DESIGN; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PROTEOMICS;

EID: 84903582579     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9607-6     Document Type: Review

References (89)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36. doi:10.1038/nrd3028.
2. Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, et al. Variability in P-glycoprotein inhibitory potency (IC(5)(0)) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos. 2013;41(7):1347-66. doi:10.1124/dmd.112.050500.
3. Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, et al. Application of receiver operating characteristic analysis to refi ne the prediction of potential digoxin drug interactions. Drug Metab Dispos. 2013;41(7):1367-74. doi:10.1124/dmd.112.050542.
4. Ghibellini G, Johnson BM, Kowalsky RJ, Heizer WD, Brouwer KL. A novel method for the determination of biliary clearance in humans. AAPS J. 2004;6(4):e33. doi:10.1208/aapsj060433.
5. Li N, Singh P, Mandrell KM, Lai Y. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol Pharm. 2010;7(3):630-41. doi:10.1021/mp9001574.
6. Li N, Zhang Y, Hua F, Lai Y. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos. 2009;37(1):66-73. doi:10.1124/dmd.108.023234.
7. Zhang Y, Li N, Brown PW, Ozer JS, Lai Y. Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples. Rapid Commun Mass Spectrom. 2011;25(12):1715-24. doi:10.1002/rcm.5026.
8. Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell. 2009;138(4):795-806. doi:10.1016/j.cell.2009.05.051.
9. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006;5(4):573-88. doi:10.1074/mcp.M500331-MCP200.
10. Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome p450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos. 2014;42(4):500-10. doi:10.1124/dmd.113.055632.
11. Russell MR, Achour B, McKenzie EA, Lopez R, Harwood MD, Rostami-Hodjegan A, et al. Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J Proteome Res. 2013;12(12):5934-42. doi:10.1021/pr400279u.
12. Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, et al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos. 2014;42(1):78-88. doi:10.1124/dmd.113.053819.
13. Prasad B, Lai Y, Lin Y, Unadkat JD. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci. 2013;102(3):787-93. doi:10.1002/jps.23436.
14. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9(6):555-66. doi:10.1038/nmeth.2015.
15. Arnott D, Kishiyama A, Luis EA, Ludlum SG, Marsters Jr JC, Stults JT. Selective detection of membrane proteins without antibodies: a mass spectrometric version of the Western blot. Mol Cell Proteomics. 2002;1(2):148-56.
16. Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B, et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods. 2010;7(1):43-6. doi:10.1038/nmeth.1408.
17. Picotti P, Aebersold R, Domon B. The implications of proteolytic background for shotgun proteomics. Mol Cell Proteomics. 2007;6(9):1589-98. doi:10.1074/mcp.M700029-MCP200. (Pubitemid 47506169)
18. Li N, Nemirovskiy OV, Zhang Y, Yuan H, Mo J, Ji C, et al. Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem. 2008;380(2):211-22. doi:10.1016/j.ab.2008.05.032.
19. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, et al . Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008;25(6):1469-83. doi:10.1007/s11095-008-9532-4.
20. Uchida Y, Tachikawa M, Obuchi W, Hoshi Y, Tomioka Y, Ohtsuki S, et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood- brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS. 2013;10(1):21. doi:10.1186/2045-8118-10-21.
21. Yoneyama T, Ohtsuki S, Ono M, Ohmine K, Uchida Y, Yamada T, et al. Quantitative targeted absolute proteomics-based largescale quantifi cation of proline-hydroxylated alpha-fibrinogen in plasma for pancreatic cancer diagnosis. J Proteome Res. 2013;12(2):753-62. doi:10.1021/pr3008144.
22. Groer C, Bruck S, Lai Y, Paulick A, Busemann A, Heidecke CD, et al. LC-MS/MS-based quanti fication of clinically relevant intestinal uptake and ef flux transporter proteins. J Pharm Biomed Anal. 2013;85:253-61. doi:10.1016/j.jpba.2013.07.031.
23. Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res. 2013;12(10):4402-13. doi:10.1021/pr4004213.
24. Fusaro VA, Mani DR, Mesirov JP, Carr SA. Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol. 2009;27(2):190-8. doi:10.1038/nbt.1524.
25. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222. doi:10.1038/msb.2008.61.
26. Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quanti fication of proteins and post-translational modi fi cations. Methods. 2005;35(3):265-73. doi:10.1016/j.ymeth.2004.08.018. (Pubitemid 40255592)
27. Chalkley R. Instrumentation for LC-MS/MS in proteomics. Methods Mol Biol. 2010;658:47-60. doi:10.1007/978-1-60761-780-8-3.
28. Bronstrup M. Absolute quantification strategies in proteomics based on mass spectrometry. Expert Rev Proteomics. 2004;1(4):503-12. doi:10.1586/ 14789450.1.4.503. (Pubitemid 43826415)
29. Sherwood CA, Eastham A, Lee LW, Risler J, Vitek O, Martin DB. Correlation between y-type ions observed in ion trap and triple quadrupole mass spectrometers. J Proteome Res. 2009;8(9):4243-51. doi:10.1021/pr900298b.
30. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A. 2003;100(12):6940-5. doi:10.1073/pnas.0832254100. (Pubitemid 36706372)
31. Barr JR, Maggio VL, Patterson Jr DG, Cooper GR, Henderson LO, Turner WE, et al. Isotope dilution-mass spectrometric quanti fi cation of speci fi c proteins: model application with apolipoprotein A-I. Clin Chem. 1996;42(10):1676-82. (Pubitemid 26354748)
32. Zhang G, Annan RS, Carr SA, Neubert TA. Overview of peptide and protein analysis by mass spectrometry. Curr Protoc Protein Sci. 2010;Chapter 16:Unit16 1. doi:10.1002/0471140864.ps1601s62.
33. Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics. 2009;72(5):740-9. doi:10.1016/j.jprot.2009.03.007.
34. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J Mass Spectrom. 2009;44(12):1637-60. doi:10.1002/jms.1692.
35. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1(5):376-86.
36. Rauniyar N, McClatchy DB, Yates 3rd JR. Stable isotope labeling of mammals (SILAM) for in vivo quantitative proteomic analysis. Methods. 2013;61(3):260-8. doi :10.1016/j.ymeth.2013.03.008.
37. Qiu X, Bi YA, Balogh LM, Lai Y. Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. J Pharm Sci. 2013;102(9):3252-63. doi:10.1002/jps.23582.
38. Geiger T, Wisniewski JR, Cox J, Zanivan S, Kruger M, Ishihama Y, et al. Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat Protoc. 2011;6(2):147-57. doi:10.1038/nprot.2010.192.
39. Hanke S, Besir H, Oesterhelt D, Mann M. Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Proteome Res. 2008;7(3):1118-30. doi:10.1021/pr7007175.
40. Harsha HC, Molina H, Pandey A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc. 2008;3(3):505-16. doi:10.1038/nprot.2008.2. (Pubitemid 351372235)
41. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc. 2006;1(6):2650-60. doi:10.1038/nprot.2006.427.
42. Ong SE, Mann M. Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol Biol. 2007;359:37-52. doi:10.1007/978-1-59745-255-7-3. (Pubitemid 350183220)
43. Brun V, Dupuis A, Adrait A, Marcellin M, Thomas D, Court M, et al. Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol Cell Proteomics. 2007;6(12):2139-49. doi:10.1074/mcp.M700163-MCP200.
44. Ishihama Y, Sato T, Tabata T, Miyamoto N, Sagane K, Nagasu T, et al. Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards. Nat Biotechnol. 2005;23(5):617-21. doi:10.1038/nbt1086. (Pubitemid 41724902)
45. Lebert D, Dupuis A, Garin J, Bruley C, Brun V. Production and use of stable isotope-labeled proteins for absolute quantitative proteomics. Methods Mol Biol. 2011;753:93-115. doi:10.1007/978-1-61779-148-2-7.
46. Li N, Bi YA, Duignan DB, Lai Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm. 2009;6(4):1180-9. doi:10.1021/mp900044x.
47. Li N, Palandra J, Nemirovskiy OV, Lai Y. LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal Chem. 2009;81(6):2251-9. doi:10.1021/ac8024009.
48. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, et al. Quantitative targeted absolute proteomics of human blood- brain barrier transporters and receptors. J Neurochem. 2011;117(2):333-45. doi:10.1111/j.1471-4159.2011.07208.x.
49. Sakamoto A, Matsumaru T, Ishiguro N, Schaefer O, Ohtsuki S, Inoue T, et al. Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and Udp-glucuronosyltransferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometry with nano-liquid chromatography. J Pharm Sci. 2011;100(9):4037-43. doi:10.1002/jps.22591.
50. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, Dauchy S, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm. 2011;8(4):1332-41. doi:10.1021/mp200129p.
51. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579-88. doi:10.1124/jpet.111.184200.
52. Balogh LM, Kimoto E, Chupka J, Zhang H, Lai Y. Membrane protein quanti fi cation by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family. J Proteomics Bioinforma. 2012;S4(003):1-8.
53. Helenius A, McCaslin DR, Fries E, Tanford C. Properties of detergents. Methods Enzymol. 1979;56:734-49.
54. Lin Y, Zhou J, Bi D, Chen P, Wang X, Liang S. Sodium-deoxycholate- assisted tryptic digestion and identification of proteolytical l y resistant proteins. Anal Biochem. 2008;377(2):259-66. doi:10.1016/j.ab.2008.03.009.
55. FDA-Guidance. Guidance for industry: bioanalytical method validation. http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM368107pdf. 2013.
56. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, et al. In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther. 2013;94(1):95-112. doi:10.1038/clpt.2013.81.
57. Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos. 1999;27(6):637-44. (Pubitemid 29252436)
58. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther. 1999;289(3):1592-9.
59. Bi YA, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos. 2006;34(9):1658-65. doi:10.1124/dmd.105.009118. (Pubitemid 44285409)
60. Pfeifer ND, Hardwick RN, Brouwer KL. Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol. 2014;54:509-35. doi:10.1146/annurev-pharmtox-011613-140021.
61. Reid LM, Jefferson DM. Culturing hepatocytes and other differentiated cells. Hepatology. 1984;4(3):548-59. (Pubitemid 14116662)
62. Chandra P, Lecluyse EL, Brouwer KL. Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes. In Vitro Cell Dev Biol Anim. 2001;37(6):380-5. doi:10.1007/BF02577575. (Pubitemid 32756849)
63. Turncliff RZ, Tian X, Brouwer KL. Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem Pharmacol. 2006;71(10):1520-9. doi:10.1016/j.bcp.2006.02. 004.
64. Tchaparian EH, Houghton JS, Uyeda C, Grillo MP, Jin L. Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos. 2011;39(12):2387-94. doi:10.1124/dmd.111.039545.
65. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, et al. Characterization of Organic Anion Transporting Polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm. 2012;9:3535-42. doi:10.1021/mp300379q.
66. Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, et al. Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos. 2011;39(9):1503-10. doi:10.1124/dmd.111.038968.
67. Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, et al. Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci. 2011;100(11):4974-85. doi:10.1002/jps.22674.
68. Poller B, Drewe J, Krahenbuhl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol. 2010;30(1):63-70. doi:10.1007/s10571- 009-9431-1.
69. Dickens D, Webb SD, Antonyuk S, Giannoudis A, Owen A, Radisch S, et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013;85(11):1672-83. doi:10.1016/j.bcp.2013.03.022.
70. Poller B, Gutmann H, Krahenbuhl S, Weksler B, Romero I, Couraud PO, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008;107(5):1358-68.
71. Weksler B, Romero IA, Couraud PO. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS. 2013;10(1):16. doi:10.1186/2045-8118-10-16.
72. Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, et al. ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood- brain barrier cell line. Mol Pharm. 2010;7(4):1057-68. doi:10.1021/mp900178j.
73. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol. 2009;77(5):897-909. doi:10.1016/j.bcp.2008.11.001.
74. Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol Pharm. 2013;10(1):289-96. doi:10.1021/mp3004308.
75. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci. 2011;100(9):3547-59. doi:10.1002/jps.22612.
76. Lai Y. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin Drug Metab Toxicol. 2009;5(10):1175-87. doi:10.1517/17425250903127234.
77. Niessen J, Jedlitschky G, Grube M, Kawakami H, Kamiie J, Ohtsuki S, et al. Expression of ABC-type transport proteins in human platelets. Pharmacogenet Genomics. 2010;20(6):396-400. doi:10.1097/FPC.0b013e32833997b0.
78. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, et al. Quantitative membrane protein expression at the blood - brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci. 2011;100(9):3939-50. doi:10.1002/jps.22487.
79. Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, et al. Quantitative assessment of the contribution of sodiumdependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos. 2013;34(8):452-61. doi:10.1002/bdd.1861.
80. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793-806. doi:10.1053/j.gastro. 2006.02.034.
81. Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005;57(10):1305-11. doi:10.1211/jpp.57.10.0009. (Pubitemid 41545896)
82. +-dependent taurocholate cotransporting polypeptide (NTCP). Eur J Pharm Sci. 2011;44(4):487-96. doi:10.1016/j.ejps.2011.09.009.
83. Proc JL, Kuzyk MA, Hardie DB, Yang J, Smith DS, Jackson AM, et al. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J Proteome Res. 2010;9(10):5422-37. doi:10.1021/pr100656u.
84. Klammer AA, MacCoss MJ. Effects of modifi ed digestion schemes on the identification of proteins from complex mixtures. J Proteome Res. 2006;5(3):695-700. doi:10.1021/pr050315j. (Pubitemid 43372210)
85. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40(1):83-92. doi:10.1124/dmd.111.042259.
86. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, et al. Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos. 2012;40(1):93-103. doi:10.1124/dmd.111. 042275.
87. Atkinson Jr AJ, Smith BP. Models of physiology and physiologically based models in clinical pharmacology. Clin Pharmacol Ther. 2012;92(1):3-6. doi:10.1038/clpt.2012.67.
88. Smith BJ. An industrial perspective on contemporary applications of PBPK models in drug discovery and development. Biopharm Drug Dispos. 2012;33(2):53-4. doi:10.1002/bdd.1778.
89. Wu CC, Yates 3rd JR. The application of mass spectrometry to membrane proteomics. Nat Biotechnol. 2003;21(3):262-7. doi:10.1038/nbt0303-262. (Pubitemid 36314809)